AVEO Oncology reported the appointment of David Crist as Vice President of Sales. According to a media release, in this role, Crist will be responsible for building out AVEO's sales force in anticipation of the potential approval and launch of tivozanib, the company's next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma.